CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a lower radiation dose beat throat cancer with fewer side effects?
Disease control OngoingThis study is testing if a lower dose of radiation combined with an immunotherapy drug (nivolumab) works as well as the standard, higher-dose radiation combined with chemotherapy (cisplatin) for treating early-stage throat cancer linked to HPV in non-smokers. The goal is to contr…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 18:45 UTC
-
Can a year of Immune-Boosting drug keep throat cancer from coming back?
Disease control OngoingThis study is for people with intermediate-risk, HPV-positive throat cancer that has spread to nearby lymph nodes. After finishing standard treatment with chemotherapy and radiation, patients are randomly assigned to either receive a year of an immunotherapy drug (nivolumab) or t…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo attack on HPV throat cancer: can we boost the immune system to fight tumors?
Disease control OngoingThis study is testing a new combination treatment for people with a specific type of advanced throat cancer caused by HPV. It combines two immunotherapy drugs (nivolumab and ipilimumab) that help the body's immune system fight cancer, along with a targeted, lower-dose radiation t…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC